Clinical Trials · NCT02351128

Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues

CompletedPhase 2Lanreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
University Hospital, Grenoble
Enrollment
35
Start date
Apr 2015
Locations
1 site, France
Primary endpoint
Percentage of patient with positive response according to the RECIST 1.1 criteria
View Lanreotide compound reference